Literature DB >> 11322261

Analysis of combinations of antiviral drugs and design of effective multidrug therapies.

M N Prichard1, C Shipman.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 11322261

Source DB:  PubMed          Journal:  Antivir Ther        ISSN： 1359-6535


× No keyword cloud information.
  28 in total

1.  Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication.

Authors:  Victor E Buckwold; Jiayi Wei; Michelle Wenzel-Mathers; Julie Russell
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

2.  The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors.

Authors:  Shirit Einav; Hadas D Sobol; Elizabeth Gehrig; Jeffrey S Glenn
Journal:  J Infect Dis       Date:  2010-07-01       Impact factor: 5.226

3.  Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo.

Authors:  Julia Ma; Xuexiang Zhang; Veronica Soloveva; Travis Warren; Fang Guo; Shuo Wu; Huagang Lu; Jia Guo; Qing Su; Helen Shen; Eric Solon; Mary Ann Comunale; Anand Mehta; Ju-Tao Guo; Sina Bavari; Yanming Du; Timothy M Block; Jinhong Chang
Journal:  Antiviral Res       Date:  2017-12-15       Impact factor: 5.970

4.  Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction.

Authors:  Toshihiko Nishimura; Toshiko Nishimura; Yajing Hu; Manhong Wu; Edward Pham; Hiroshi Suemizu; Menashe Elazar; Michael Liu; Ramazan Idilman; Cihan Yurdaydin; Peter Angus; Catherine Stedman; Brian Murphy; Jeffrey Glenn; Masato Nakamura; Tatsuji Nomura; Yuan Chen; Ming Zheng; William L Fitch; Gary Peltz
Journal:  J Pharmacol Exp Ther       Date:  2012-11-08       Impact factor: 4.030

5.  In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.

Authors:  Katyna Borroto-Esoda; Florence Myrick; Joy Feng; Jerry Jeffrey; Phillip Furman
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  Peptidyl aldehyde NK-1.8k suppresses enterovirus 71 and enterovirus 68 infection by targeting protease 3C.

Authors:  Yaxin Wang; Ben Yang; Yangyang Zhai; Zheng Yin; Yuna Sun; Zihe Rao
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

7.  A Conserved Inhibitory Mechanism of a Lycorine Derivative against Enterovirus and Hepatitis C Virus.

Authors:  Yu Guo; Yaxin Wang; Lin Cao; Peng Wang; Jie Qing; Qizhen Zheng; Luqing Shang; Zheng Yin; Yuna Sun
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

8.  Antiviral activity of nucleoside analogues against norovirus.

Authors:  Verónica P Costantini; Tony Whitaker; Leslie Barclay; David Lee; Tamara R McBrayer; Raymond F Schinazi; Jan Vinjé
Journal:  Antivir Ther       Date:  2012-08-14

9.  Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.

Authors:  Huiling Yang; Margaret Robinson; Amoreena C Corsa; Betty Peng; Guofeng Cheng; Yang Tian; Yujin Wang; Rowchanak Pakdaman; Marian Shen; Xiaoping Qi; Hongmei Mo; Chin Tay; Steve Krawczyk; X Christopher Sheng; Choung U Kim; Chris Yang; William E Delaney
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

10.  The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

Authors:  Joy Y Feng; John K Ly; Florence Myrick; Derrick Goodman; Kirsten L White; Evguenia S Svarovskaia; Katyna Borroto-Esoda; Michael D Miller
Journal:  Retrovirology       Date:  2009-05-13       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.